135 related articles for article (PubMed ID: 35961783)
1. Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
Jessa R; Chien N; Villa D; Freeman CL; Slack GW; Savage KJ; Scott DW; Sehn LH; Song KW; Gerrie AS
Br J Haematol; 2022 Oct; 199(2):230-238. PubMed ID: 35961783
[TBL] [Abstract][Full Text] [Related]
2. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG
Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556
[TBL] [Abstract][Full Text] [Related]
3. HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa.
Rapiti N; Peer N; Abdelatif N; Rapiti P; Moosa Y
HIV Med; 2022 Sep; 23(8):837-848. PubMed ID: 35229978
[TBL] [Abstract][Full Text] [Related]
4. HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients.
Mai B; Wang W; Lin M; Hu S; Wang XI; Chen L; Wahed A; Nguyen A; Ma HY; Medeiros LJ; Hu Z
AIDS; 2020 Oct; 34(12):1735-1743. PubMed ID: 32889849
[TBL] [Abstract][Full Text] [Related]
5. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency.
Ramadan KM; Shenkier T; Sehn LH; Gascoyne RD; Connors JM
Ann Oncol; 2007 Jan; 18(1):129-135. PubMed ID: 17018705
[TBL] [Abstract][Full Text] [Related]
6. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
Pinnix CC; Shah JJ; Chuang H; Costelloe CM; Medeiros LJ; Wogan CF; Reed V; Smith GL; Milgrom S; Patel K; Huo J; Turturro F; Romaguera J; Fayad L; Oki Y; Fanale MA; Westin J; Nastoupil L; Hagemeister FB; Rodriguez A; Qazilbash M; Shah N; Bashir Q; Ahmed S; Nieto Y; Hosing C; Rohren E; Dabaja B
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):122-8. PubMed ID: 26795083
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
Gui L; He XH; Liu P; Yang JL; Qin Y; Zhou SY; Yang S; Zhang CG; Shi YK
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):762-767. PubMed ID: 27719718
[TBL] [Abstract][Full Text] [Related]
9. Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.
Marvyin K; Tjønnfjord EB; Breland UM; Tjønnfjord GE
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32994268
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
Dittus C; Grover N; Ellsworth S; Tan X; Park SI
Leuk Lymphoma; 2018 Sep; 59(9):2121-2127. PubMed ID: 29303024
[TBL] [Abstract][Full Text] [Related]
11. The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes.
Makady NF; Ramzy D; Ghaly R; Abdel-Malek RR; Shohdy KS
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e255-e263. PubMed ID: 33419717
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
Koizumi Y; Uehira T; Ota Y; Ogawa Y; Yajima K; Tanuma J; Yotsumoto M; Hagiwara S; Ikegaya S; Watanabe D; Minamiguchi H; Hodohara K; Murotani K; Mikamo H; Wada H; Ajisawa A; Shirasaka T; Nagai H; Kodama Y; Hishima T; Mochizuki M; Katano H; Okada S
Int J Hematol; 2016 Dec; 104(6):669-681. PubMed ID: 27604616
[TBL] [Abstract][Full Text] [Related]
13. HIV-negative plasmablastic lymphoma: not in the mouth.
Castillo JJ; Winer ES; Stachurski D; Perez K; Jabbour M; Milani C; Colvin GA; Butera JN
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):185-9. PubMed ID: 21575922
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Castillo JJ; Reagan JL; Sikov WM; Winer ES
Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
[TBL] [Abstract][Full Text] [Related]
15. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
16. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
17. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.
Castillo J; Pantanowitz L; Dezube BJ
Am J Hematol; 2008 Oct; 83(10):804-9. PubMed ID: 18756521
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological Characteristics and Prognosis Analysis of the Patients with Plasmablastic Lymphoma].
Feng J; Xu L; Dong HJ; Zhang N; Bai QX; Liang R; Shu MM; Yang L; Chen XQ; Gu HT; Gao GX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1350-1354. PubMed ID: 30295249
[TBL] [Abstract][Full Text] [Related]
19. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
[TBL] [Abstract][Full Text] [Related]
20. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]